Phaseline

Companies › Seismic Pharmaceuticals Operations

Seismic Pharmaceuticals Operations: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
istaroxime
Sodium/potassium-transporting ATPase inhibitor; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator
Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2Phase 2Cardiogenic ShockDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07583446istaroximePhase 2Cardiogenic ShockCardiovascularDec 2028

Targets

Na+/K+-ATPase (1) ATP1B2 (1) ATP1B1 (1) ATP1B3 (1) FXYD2 (1)

Companies with the same targets

Windtree Therapeutics

Companies built like this

Tectonic Operating Company CuraSen Therapeutics Neurimmune Foresee Pharmaceuticals Nyrada

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.